Medtronic's (MDT) OmniaSecure defibrillation lead demonstrates reliable performance in the LEADR Pivotal trial.
Growth across Cranial & Spinal Technologies, Diabetes, Cardiac Pacing and Surgical businesses contributes to Medtronic's (MDT) Q4 revenues.
While the top- and bottom-line numbers for Medtronic (MDT) give a sense of how the business performed in the quarter ended April 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.